Zürcher Nachrichten - Asia-Pacific gets new weapon in fight against drug-resistant TB

EUR -
AED 4.05586
AFN 78.957999
ALL 100.898311
AMD 432.103575
ANG 1.976787
AOA 1011.467257
ARS 1186.363518
AUD 1.745311
AWG 1.9876
AZN 1.87643
BAM 1.954087
BBD 2.229261
BDT 134.152351
BGN 1.953772
BHD 0.416176
BIF 3231.505662
BMD 1.104222
BND 1.475286
BOB 7.629483
BRL 6.218939
BSD 1.104092
BTN 94.249929
BWP 15.279831
BYN 3.613147
BYR 21642.751059
BZD 2.217774
CAD 1.554408
CDF 3172.42966
CHF 0.948974
CLF 0.027324
CLP 1048.524856
CNY 8.040448
CNH 8.038129
COP 4593.508279
CRC 556.291423
CUC 1.104222
CUP 29.261883
CVE 112.685325
CZK 25.073542
DJF 196.242018
DKK 7.461626
DOP 69.679844
DZD 146.67643
EGP 55.864685
ERN 16.56333
ETB 143.214489
FJD 2.556163
FKP 0.851043
GBP 0.843768
GEL 3.036243
GGP 0.851043
GHS 17.114226
GIP 0.851043
GMD 79.700647
GNF 9552.382551
GTQ 8.501761
GYD 231.665029
HKD 8.588794
HNL 28.265775
HRK 7.532116
HTG 143.529041
HUF 406.090928
IDR 18458.911507
ILS 4.079763
IMP 0.851043
INR 94.359084
IQD 1444.115785
IRR 46487.940849
ISK 146.205374
JEP 0.851043
JMD 172.048419
JOD 0.782868
JPY 161.544354
KES 142.703072
KGS 95.724625
KHR 4416.637221
KMF 499.828456
KPW 993.859466
KRW 1614.714394
KWD 0.340458
KYD 0.918256
KZT 555.254064
LAK 23926.815484
LBP 98898.408728
LKR 325.208576
LRD 220.835956
LSL 20.718348
LTL 3.260481
LVL 0.667933
LYD 5.333615
MAD 10.588417
MDL 19.734571
MGA 5093.722724
MKD 62.808495
MMK 2318.263231
MNT 3857.553481
MOP 8.851802
MRU 43.954051
MUR 50.532927
MVR 17.051344
MWK 1914.764226
MXN 22.015209
MYR 4.917931
MZN 70.547731
NAD 20.718348
NGN 1695.145855
NIO 40.631533
NOK 11.410279
NPR 151.045304
NZD 1.908306
OMR 0.425097
PAB 1.104222
PEN 4.057104
PGK 4.511816
PHP 63.03804
PKR 309.312831
PLN 4.235968
PYG 8802.577006
QAR 4.018956
RON 5.057577
RSD 119.055982
RUB 93.022442
RWF 1568.577853
SAR 4.141096
SBD 9.385397
SCR 15.971898
SDG 662.498791
SEK 10.816804
SGD 1.481886
SHP 0.867745
SLE 25.120995
SLL 23154.984273
SOS 629.958048
SRD 40.437351
STD 22855.165835
SVC 9.662235
SYP 14357.86896
SZL 20.718348
THB 37.663888
TJS 12.043366
TMT 3.862166
TND 3.415945
TOP 2.659637
TRY 41.973454
TTD 7.466717
TWD 36.575064
TZS 2922.401324
UAH 45.631623
UGX 4025.831038
USD 1.104222
UYU 46.647638
UZS 14290.01376
VES 77.083414
VND 28344.064062
VUV 136.448042
WST 3.128076
XAF 666.437941
XAG 0.034564
XAU 0.000355
XCD 2.989452
XDR 0.831364
XOF 666.437941
XPF 119.331742
YER 271.534362
ZAR 20.709672
ZMK 9939.317211
ZMW 30.955568
ZWL 355.559031
  • CMSC

    -0.2400

    22.26

    -1.08%

  • RIO

    -1.4700

    58.43

    -2.52%

  • NGG

    3.6100

    69.39

    +5.2%

  • RBGPF

    69.0200

    69.02

    +100%

  • AZN

    1.7000

    73.92

    +2.3%

  • GSK

    1.3700

    39.01

    +3.51%

  • SCS

    -0.7200

    10.74

    -6.7%

  • BTI

    1.6700

    41.92

    +3.98%

  • RELX

    0.4600

    51.44

    +0.89%

  • RYCEF

    -0.0200

    9.78

    -0.2%

  • JRI

    -0.2200

    12.82

    -1.72%

  • CMSD

    -0.1600

    22.67

    -0.71%

  • BCC

    -7.4400

    94.63

    -7.86%

  • VOD

    0.2500

    9.37

    +2.67%

  • BCE

    0.8400

    22.66

    +3.71%

  • BP

    -2.4700

    31.34

    -7.88%

Advertisement Image
Asia-Pacific gets new weapon in fight against drug-resistant TB
Asia-Pacific gets new weapon in fight against drug-resistant TB / Photo: Nhac NGUYEN - AFP

Asia-Pacific gets new weapon in fight against drug-resistant TB

A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.

Advertisement Image

Text size:

The region had most of the world's estimated 10.6 million new TB cases in 2022, and more than half of the 1.3 million deaths, World Health Organization (WHO) figures show.

While TB can be successfully treated with antibiotics, more than three percent of new TB patients are resistant to commonly prescribed drugs.

Until recently, treatment for these patients involved daily painful injections or a fistful of pills for 18 months or longer, while some endured severe side effects such as nausea and, in extreme cases, blindness.

Many people prematurely quit their treatment, which had a success rate of 63 percent or lower.

Now, a new drug regimen involving fewer pills and side effects is being rolled out in the Asia-Pacific, including the Philippines, Vietnam and Indonesia, where trials have shown a more than 90 percent cure rate after six months.

The treatment, known as BPaL, combines the antibiotics bedaquiline, pretomanid and linezolid, and has received regulatory approval in more than 60 countries since 2019, according to the non-profit TB Alliance, which developed it.

The WHO updated its guidelines in 2022 to allow BPaL to be used with or without a fourth antibiotic called moxifloxacin.

BPaL has been life-changing for Filipino cook Efifanio Brillante, who was diagnosed with drug-resistant TB in June 2022 and initially went on an older form of treatment.

Brillante, 57, was swallowing 20 tablets a day, but it left him feeling so nauseous that he couldn't work or eat.

He stopped the medication after two weeks even though he knew the decision could be fatal.

"It's very difficult. You're always in bed," Brillante told AFP about his experience of having TB.

"Sometimes I couldn't even breathe."

The following month, Brillante joined a BPaL trial at the Jose B Lingad Memorial General Hospital in Pampanga province, north of the Philippine capital Manila.

He took between three and seven pills a day and was cured after six months.

"I'm very thankful that I was healed," Brillante told AFP in his home.

"If I didn't take that BPaL, I might already be buried in the cemetery."

- 'A curable disease' -

TB, once called consumption, is caused by a bacteria that primarily attacks the lungs and is transmitted through the air by infected people, for example by coughing.

While it is found in every country, poorer people living and working in overcrowded conditions are at higher risk of the disease.

Eight countries accounted for two-thirds of new TB cases in 2022: India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and the Democratic Republic of Congo.

One of the biggest challenges of treating drug-resistant TB has been getting patients to take the full course of their medication.

Even in countries where treatment is free, patients face crippling travel costs to hospitals and loss of income, or even their job, due to the illness and side-effects of the drugs, leading many to stop taking their pills.

In Vietnam, most people diagnosed with TB are from low-income families, Hoang Thi Thanh Thuy from the Vietnam National Tuberculosis Program told AFP.

Nearly everyone with drug-resistant TB endured "catastrophic" expenses over the period of their treatment, she said.

"All of these difficulties can affect patient compliance and lead to poor treatment and increasing drug resistance," Thuy said.

Identifying people with TB is also a challenge.

In Indonesia, some healthcare facilities are still not able to properly diagnose the disease, said Imran Pambudi of the health ministry.

Fear of social stigma from a positive diagnosis is also common.

"We're trying to educate them that TB is a curable disease," said Irene Flores, who led the BPaL trial at the Jose B Lingad Memorial General Hospital in the Philippines.

"If they come early, we can prevent complications."

- More investment needed -

After years of decline, the number of people falling ill with TB and drug-resistant tuberculosis began increasing during the Covid-19 pandemic, which disrupted diagnosis and treatment, the WHO said previously.

After gargantuan global efforts to develop a vaccine against the coronavirus, the WHO has called for increased funding to fight TB.

"As TB stopped being a high income-country problem, motivation to invest in research and development for new TB drugs dried up," said Sandeep Juneja, senior vice president of market access at the TB Alliance.

To help accelerate the rollout of BPaL, with or without moxifloxacin, the TB Alliance has set up a "knowledge hub" in Manila to provide training and assistance to other countries.

In India, where BPaL has been approved, there is growing impatience for it to be introduced into health clinics given the country's world-beating caseload.

"BPaL should be rolled out soon because it will spare patients a lot of headaches and provide psychological relief too, besides reducing cost of treatment in the long run," said Ravikant Singh, founder of advocacy group Doctors For You.

Juneja said the new regimen meant treating drug-resistant TB was no longer a guessing game of whether a patient would survive or not.

But more is needed to be done, he added.

"I hope this is... just the beginning of a new era of TB treatment where they will be even simpler, even shorter."

burs-pam/amj/dhw/jfx

T.L.Marti--NZN

Advertisement Image